Efficacy and Safety of SPD503 in Combination With Psychostimulants
Status:
Completed
Trial end date:
2009-12-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of SPD503 in subjects with
ADHD when co-administered with psychostimulants in children and adolescents aged 6-17 years
with a diagnosis of ADHD with a sub-optimal, partial response to stimulants.